AMAG - AMAG Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.80
-0.10 (-0.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close24.90
Open24.85
Bid21.65 x 800
Ask27.50 x 2900
Day's Range24.35 - 24.95
52 Week Range11.93 - 26.10
Volume188,028
Avg. Volume669,428
Market Cap854.925M
Beta0.33
PE Ratio (TTM)N/A
EPS (TTM)-6.43
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.78
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of AMAG earnings conference call or presentation 2-Aug-18 12:00pm GMT

    Q2 2018 AMAG Pharmaceuticals Inc Earnings Call

  • Note to Musk: Tesla isn't the only company targeted by short sellers. Here's who tops the list in Mass.
    American City Business Journals6 days ago

    Note to Musk: Tesla isn't the only company targeted by short sellers. Here's who tops the list in Mass.

    Investors betting on Tesla’s stock stumbling took a beating this week when shares in the company rallied after CEO Elon Musk tweeted that he was considering taking the company private.

  • PR Newswire10 days ago

    California Cryobank And Cord Blood Registry Combine To Create A Leading Life Sciences Platform

    LOS ANGELES , Aug. 6, 2018 /PRNewswire/ --  California Cryobank , the world's leading donor sperm and donor egg bank, announced today that it has been acquired by GI Partners, a private equity investment ...

  • GlobeNewswire10 days ago

    AMAG Pharmaceuticals Completes Divestiture of Cord Blood Registry®

    AMAG Pharmaceuticals, Inc. (AMAG) today announced it has closed the previously announced divestiture of Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. The purchase price is subject to customary purchase price adjustments with respect to working capital, cash, indebtedness and transaction expenses as previously disclosed. “Completing the divestiture of CBR is an important step in the successful execution of AMAG’s strategic plan which focuses on growing and diversifying our pharmaceutical business,” said William Heiden, president and chief executive officer at AMAG.

  • GlobeNewswire10 days ago

    AMAG Pharmaceuticals Appoints Brian Robinson, M.D. as Senior Vice President of Medical Affairs

    AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of Brian Robinson, M.D. as senior vice president, medical affairs, reporting into Julie Krop, M.D., chief medical officer and executive vice president, development.

  • AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Misses Revenue Estimates
    Zacks14 days ago

    AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Misses Revenue Estimates

    AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -257.14% and -6.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press14 days ago

    AMAG Pharmaceuticals: 2Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 58 cents. Losses, adjusted to account for discontinued operations, were 75 cents per share. The results fell short of ...

  • GlobeNewswire14 days ago

    AMAG Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    Achieved 12% revenue growth and record quarterly sales. Raising full year revenue and adjusted EBITDA guidance for pharmaceutical products. Conference call scheduled for 8:00 a.m. ET today.

  • ACCESSWIRE14 days ago

    AMAG Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:00 AM Eastern ...

  • GlobeNewswire21 days ago

    AMAG Pharmaceuticals to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Thursday, August 2, 2018 at 8:00 a.m. ET

    WALTHAM, Mass., July 26, 2018-- AMAG Pharmaceuticals, Inc. today announced that its second quarter 2018 financial results will be released on Thursday, August 2, 2018 before the U.S. financial markets ...

  • Moody'slast month

    GI Chill Acquisition LLC -- Moody's assigns a B3 CFR to GI Chill Acquisition LLC; stable outlook

    Moody's Investors Service ("Moody's") assigned a B3 Corporate Family Rating (CFR) to GI Chill Acquisition LLC (doing business as California Cryobank Life Sciences) At the same time, Moody's assigned a B3-PD Probability of Default Rating (PDR) and a B2 rating to the company's new first lien senior secured term loan and revolver. Proceeds from the debt issuance, along with equity and a new second lien term loan (not rated), will be used in part to fund the acquisition and combination of California Cryobank and Cord Blood Registry by private equity firm, GI Partners. GI Chill's B3 Corporate Family Rating reflects Moody's view that the company will operate with high debt/EBITDA of more than 8.5 times on a GAAP basis (more than 6.5 times if adjusting for deferred revenues related to pre-paid subscriptions) over the next 12-18 months.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within The Stars Group, AMAG Pharmaceuticals, ResMed, WestRock, Briggs & Stratton, and II-VI — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, June 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...

  • The Wall Street Journal2 months ago

    [$$] GI Partners Buys Cord Blood Registry and Sperm and Egg Bank

    GI Partners is buying two medical-storage companies to take advantage of the growing reproductive sciences field. GI is also buying California Cryobank, a donor sperm and egg bank, from health-care investors Longitude Capital and NovaQuest Capital, for an undisclosed amount. California Cryobank’s donor sperm and egg banks have worked with more than 75,000 families since 1977.

  • PR Newswire2 months ago

    California Cryobank And Cord Blood Registry To Be Combined By GI Partners To Create A Leading Life Sciences Platform

    LOS ANGELES, June 15, 2018 /PRNewswire/ -- California Cryobank, the world's leading donor sperm and donor egg bank, announced today that it has signed a definitive agreement for GI Partners, a private equity investment firm, to acquire the company from leading healthcare investors Longitude Capital and NovaQuest Capital. In a separate transaction announced today, GI Partners has also entered into a definitive agreement with AMAG Pharmaceuticals, Inc. (AMAG) to acquire Cord Blood Registry (CBR), the world's largest stem cell collection and storage company.

  • GlobeNewswire2 months ago

    AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry®

    AMAG Pharmaceuticals, Inc. (AMAG) today announced it has entered into a definitive agreement to divest Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. “The divestiture of CBR is an important step as we execute on AMAG's strategic plan, which includes leveraging our proven expertise in drug development and commercialization to bring innovative products to patients with unmet medical needs,” said William Heiden, president and chief executive officer at AMAG.

  • ACCESSWIRE2 months ago

    Initiating Free Research Reports on ArQule and Three Other Biotech Equities

    In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.

  • GlobeNewswire2 months ago

    AMAG Pharmaceuticals, Inc. and March of Dimes Announce Collaboration to Improve Health of Mothers and Babies

    AMAG Pharmaceuticals, Inc. (AMAG) and March of Dimes today announced a strategic corporate partnership focused on a shared commitment to improve maternal health and birth outcomes, as well as to reduce health inequities. Through the partnership, AMAG will participate in the March of Dimes Prematurity Campaign Collaborative and support the expansion of the March of Dimes’ Supportive Pregnancy Care (SPC) model, an innovative group prenatal care program. “AMAG’s commitment to support the health of patients and families encompasses far more than the therapies we offer to help moms and babies.

  • GlobeNewswire2 months ago

    AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide

    AMAG Pharmaceuticals, Inc. (AMAG) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bremelanotide, a first-in-class melanocortin 4 receptor agonist designed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The Prescription Drug User Fee Act (PDUFA) date for completion of FDA review of the bremelanotide NDA is March 23, 2019.

  • GlobeNewswire3 months ago

    AMAG Pharmaceuticals to Present at Upcoming Investor Conference

    AMAG Pharmaceuticals, Inc. (AMAG) today announced that management will participate in the Jefferies 2018 Healthcare Conference on Tuesday, June 5th  at 3:30 p.m. ET. AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.

  • ACCESSWIRE3 months ago

    Wired News – Auris Medical Reported Publication Related to AM-111 in Peer-Reviewed Scientific Journal Hearing Research

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Auris Medical Holding AG (NASDAQ: EARS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EARS as the Company's latest news hit the wire. On May 04, 2018, the Switzerland-based biopharmaceutical Company announced that the article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111, the Company's investigational treatment for acute inner ear hearing loss, was published in Hearing Research, one of the leading journals in the otorhinolaryngology field. The peer-reviewed article "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)" was published.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of AMAG earnings conference call or presentation 3-May-18 12:00pm GMT

    Q1 2018 AMAG Pharmaceuticals Inc Earnings Call

  • AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View
    Zacks3 months ago

    AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View

    AMAG incurs wider-than-expected loss in the first quarter of 2018. The company raised 2018 revenue guidance.

  • Associated Press3 months ago

    AMAG Pharmaceuticals: 1Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of $1.59 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...